MYC regulation of a "poor-prognosis" metastatic cancer cell state
Name
Wolfer_MYC regulation.pdf
Size
951.32 KB
Format
Adobe PDF
Checksum (MD5)
064f97f9be0d6243d2eb487e516c7f14
Author(s)
Mesirov, Jill P.
Wolfer, Anita
Wittner, Ben S.
Irimia, Daniel
Flavin, Richard J.
Lupien, Mathieu
Gunawardane, Ruwanthi N.
Meyer, Clifford A.
Lightcap, Eric S.
Tamayo, Pablo
Date Issued
February 2010
Journal
Proceedings of the National Academy of Sciences
Publisher
National Academy of Sciences (U.S.)
Citation
Wolfer, A., B. S. Wittner, D. Irimia, R. J. Flavin, M. Lupien, R. N. Gunawardane, C. A. Meyer, et al. “MYC Regulation of a ‘Poor-Prognosis’ Metastatic Cancer Cell State.” Proceedings of the National Academy of Sciences 107, no. 8 (February 23, 2010): 3698–3703.
Version
Final published version
Abstract
Gene expression signatures are used in the clinic as prognostic tools to determine the risk of individual patients with localized breast tumors developing distant metastasis. We lack a clear understanding, however, of whether these correlative biomarkers link to a common biological network that regulates metastasis. We find that the c-MYC oncoprotein coordinately regulates the expression of 13 different “poor-outcome” cancer signatures. In addition, functional inactivation of MYC in human breast cancer cells specifically inhibits distant metastasis in vivo and invasive behavior in vitro of these cells. These results suggest that MYC oncogene activity (as marked by “poor-prognosis” signature expression) may be necessary for the translocation of poor-outcome human breast tumors to distant sites.
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1073/pnas.0914203107
